Under construction – not a live service
Sign in
Taking people in FranceNo phase

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

Key facts

Who runs it
W.L.Gore & Associates
Where
Strasbourg, FranceSee the siteAlso in 9 other countries, 36 sites
Trial code
Status
Recruiting
People taking part
1,500 people, planned
Started
19 Jun 2025
Expected to end
Aug 2038
Type of study
Observational, 2 groups
Treatments tested
  • Endovascular
Record updated
19 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements
  • Patient has been or is intended to be treated with an eligible registry device.*
  • Patient is age ≥ 18 years at time of informed consent signature; The intent to treat a patient with a Gore product must be made prior to soliciting for possible registry participation. If pre-procedure consent is not feasible due to emergent situation, consent prior to the time of discharge for the index procedure is acceptable

Who cannot take part

  • Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or investigational device study* within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol; The term "study" does not apply to other observational registries or quality improvement projects. Collection of Registry Device performance from interventional studies may be permissible provided device application is not investigational and there are no novel requirements that alter follow-up conduct (i.e., protocol-mandated interventions)
  • Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures
  • Patient with exclusion criteria required by local law

Where in France

Also in 9 other countries, 36 sites

  • centre Hospitalier Universitaire StrasbourgStrasbourg, FranceContact: Salomé Kuntz, M.D.Taking people

About the trial

What the trial wants to find out

An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w/AC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.

The 2 groups in the trial

  • Aneurysm/Other Isolated Lesion

    Treatment: Endovascular

  • Dissection

    Treatment: Endovascular

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
19 August 2026